As an allosteric activator of the calcium-sensing receptor, cinacalcet inhibits PTH release, as well as lowers serum calcium, making the drug ideal for patients with hyperparathyroidism and hypercalcemia [38]. Here, CASR is linked to hyperparathyroidism.